Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 0: clinchem.2005.065581v1, 2006; 10.1373/clinchem.2005.065581
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2005.065581v1
52/6/1144    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Papassotiriou, J.
Right arrow Articles by Bergmann, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Papassotiriou, J.
Right arrow Articles by Bergmann, A.

Received on December 20, 2005
Accepted on March 28, 2006

Endocrinology and Metabolism

Immunoluminometric Assay for Measurement of the C-Terminal Endothelin-1 Precursor Fragment in Human Plasma

Jana Papassotiriou 1, Nils G. Morgenthaler 1*, Joachim Struck 1, Christine Alonso 1, Andreas Bergmann 1

1 Research Department, B.R.A.H.M.S AG, Biotechnology Centre, Hennigsdorf/Berlin, Germany

* To whom correspondence should be addressed. E-mail: n.morgenthaler{at}brahms.de.

Background: Endothelin-1 (ET-1), a potent vasoconstrictor, is difficult to measure because of its instability and its binding to receptors and plasma proteins. We report a rapid, robust way to indirectly quantify ET-1 release by measuring the C-terminal ET-1 precursor fragment (CT-proET-1) without an extraction step.

Methods: In plasma samples from healthy individuals, patients with congestive heart failure (CHF), and patients with sepsis, we measured CT-proET-1 with a sandwich immunoluminometric assay that uses 2 polyclonal antibodies to amino acids 168-212 of pre-proET-1. We also correlated CT-proET-1 concentrations with bigET-1 measurements.

Results: The assay yielded results within 3 h and showed linear dilution with an analytical detection limit of 0.4 pmol/L and an interlaboratory CV <10% for values >10 pmol/L. Ex vivo CT-proET-1 was stable (<10% loss of immunoreactivity) in EDTA-, heparin-, and citrate-plasma for at least 4 h at room temperature, 6 h at 4 °C, and in EDTA-plasma for at least 6 months at -20 °C. CT-proET-1 values followed a gaussian distribution in healthy individuals (mean, 44.3 pmol/L; range, 10.5-77.4 pmol/L) without significant differences between males and females. The correlation coefficient for CT-proET-1 vs age was 0.25 (P <0.0001). CT-proET1 was significantly (P <0.0001) increased in patients with CHF (median, 104 pmol/L; range, 50.8-315 pmol/L) and patients with sepsis (median, 189 pmol/L; range, 34.6-855 pmol/L). The correlation between CT-proET1 and bigET-1 for 43 samples was 0.80 (P <0.0001).

Conclusions: CT-proET measurement is a rapid and easy method for indirectly assessing the release of ET-1 in critically ill patients.


The following articles in journals at HighWire Press have cited this article:


Home page
 Diabetes CareHome page
C. Maier, M. Clodi, S. Neuhold, M. Resl, M. Elhenicky, R. Prager, D. Moertl, G. Strunk, A. Luger, J. Struck, et al.
Endothelial Markers May Link Kidney Function to Cardiovascular Events in Type 2 Diabetes
Diabetes Care, October 1, 2009; 32(10): 1890 - 1895.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
P Wexberg, W Sperker, N G Morgenthaler, H Heinzl, C Adlbrecht, C Plass, H D Glogar, I M Lang, and T Neunteufl
Inhomogeneous vasomotor effects of moderate selective and non-selective endothelin-receptor blockade in stable coronary artery disease
Heart, August 1, 2009; 95(15): 1258 - 1264.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
C. Adlbrecht, M. Hulsmann, G. Strunk, R. Berger, D. Mortl, J. Struck, N. G. Morgenthaler, A. Bergmann, J. Jakowitsch, G. Maurer, et al.
Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients
Eur J Heart Fail, April 1, 2009; 11(4): 361 - 366.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
G. Vila, M. Resl, D. Stelzeneder, J. Struck, C. Maier, M. Riedl, M. Hulsmann, R. Pacher, A. Luger, and M. Clodi
Plasma NT-proBNP increases in response to LPS administration in healthy men
J Appl Physiol, December 1, 2008; 105(6): 1741 - 1745.
[Abstract] [Full Text] [PDF]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
A. Piccin, C. Murphy, E. Eakins, W. Murphy, J. Kunde, C. McMahon, and O. Smith
Plasma Adrenomedullin Levels Are Elevated in Pediatric Patients with Severe Sickle Cell Anemia
Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 4795 - 4795.
[Abstract] [Full Text]

Home page
 ChestHome page
D. Stolz, M. Christ-Crain, N. G. Morgenthaler, D. Miedinger, J. Leuppi, C. Muller, R. Bingisser, J. Struck, B. Muller, and M. Tamm
Plasma Pro-Adrenomedullin But Not Plasma Pro-Endothelin Predicts Survival in Exacerbations of COPD
Chest, August 1, 2008; 134(2): 263 - 272.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. Szinnai, N. G. Morgenthaler, K. Berneis, J. Struck, B. Muller, U. Keller, and M. Christ-Crain
Changes in Plasma Copeptin, the C-Terminal Portion of Arginine Vasopressin during Water Deprivation and Excess in Healthy Subjects
J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3973 - 3978.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by the American Association for Clinical Chemistry.